GLP-1 Receptor Agonists in Chronic Kidney Disease: Connecting the Kidney to the Cardiovascular-Kidney-Metabolic Continuum
ACPE Activity Number:0204-0000-26-047-H01-P Release Date: 2/24/2026 Expiration Date: 2/24/2029 Activity Type: Application-based CE Credits: 1 contact hour Activity Fee: Member – Free / Non-Member – Not Available
This activity is a recording of a live webinar, if you claimed credit for the live activity, you should not claim credit for this activity.
Activity Overview
Chronic kidney disease (CKD) frequently coexists with diabetes, obesity, and cardiovascular disease, placing patients at high risk for adverse cardio-kidney-metabolic (CKM) outcomes. While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established for glycemic control and weight management, their role in patients with CKD continues to evolve. This activity will examine the mechanistic rationale, clinical trial evidence, and practical considerations for the use of GLP-1 RAs across the CKM continuum in patients with CKD. Emphasis will be placed on cardiovascular and kidney outcomes data, safety and tolerability considerations across stages of CKD, and clinical decision-making in complex patients where diabetes, cardiovascular disease, and kidney dysfunction intersect.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity was planned to meet the educational needs of pharmacists involved in the care of patients with chronic kidney disease, diabetes, obesity, and cardiovascular disease, including those practicing in ambulatory care, nephrology, cardiology, endocrinology, and primary care settings.
After completing this activity, the learner should be able to:
Describe the role of GLP-1 receptor agonists within the cardiovascular-kidney-metabolic continuum in patients with chronic kidney disease.
Evaluate clinical trial evidence supporting the cardiovascular and kidney effects of GLP-1 receptor agonists in patients with CKD.
Apply patient-specific factors, including stage of CKD and comorbid CKM conditions, to optimize safe and effective use of GLP-1 receptor agonists in clinical practice.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.
